PIA
CTIC

Piedmont Investment Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Piedmont Investment Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-887
Closed -$4K – 2954
2018
Q2 		$4K Buy
+887
New +$3.88K ﹤0.01% 2340

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Piedmont Investment Advisors's CTIC Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q3 2018, closing a stake of 887 shares — an estimated $4K sold.

Piedmont Investment Advisors first reported a position in CTIC in Q2 2018 and held it in 1 quarter. The position peaked at $4K in Q2 2018. 79 funds tracked by Wall St. Rank hold CTIC as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 887 CTI BioPharma Corp. (DE) Common Stock shares in Q3 2018, an estimated $4K.
  • Piedmont Investment Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $4K in Q2 2018.
  • 79 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.